e16543 Background: Advanced presentation and poor prognosis have been noted for non-white compared to non-Hispanic white melanoma patients. Socioeconomic status (SES) is thought to explain this disparity, at least in part. However, the association between SES and clinical presentation in non-white melanoma patients has not yet been defined. Methods: Demographic, race and insurance information, tumor characteristics, and follow-up data were retrieved for melanoma patients who presented to Bellevue Hospital Center, a public hospital, and the New York University Cancer Institute (NYUCI), a private academic medical center, for treatment of melanoma between 1998 and 2009. We used these data in conjunction with information from the U.S. Census Bureau (median household income, level of education) to determine patients' SES. We focused our analyses on non-white patients. Three groups of melanoma patients were compared: Bellevue Hispanic, Bellevue other race (includes Asian, Black, and other race), and NYUCI non-white. Continuous variables (age at diagnosis, income, educational level, primary tumor thickness) were analyzed using the Kruskal-Wallis test. Discrete variables (gender, clinical stage at presentation, primary anatomic site) were evaluated using the Chi- Square test. Results: 50/119 (42%) melanoma patients presenting for treatment at Bellevue were non-white (32 Hispanic, 18 other race), whereas only 27/1296 (2%) accrued at NYUCI were identified as non-white. NYUCI non-white patients were significantly more likely to have a higher median household income (p = 0.05), a higher level of education (p = 0.04), and an earlier clinical stage at presentation (p = 0.02) compared to either group of non-white Bellevue patients. At last follow-up, 78% of NYUCI non-white patients showed no evidence of disease, compared to 59% and 50% of Bellevue Hispanic and other race patients, respectively. Conclusions: Our data suggest thatnon-white melanoma patients with higherSES present at an earlier stage with better outcome. Increased screening efforts in areas of low SES are therefore warranted to improve early diagnosis of melanoma. No significant financial relationships to disclose.